If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.